NASDAQ:DRUG Bright Minds Biosciences (DRUG) Stock Price, News & Analysis $50.69 +1.48 (+3.01%) Closing price 10/2/2026 04:00 PM EasternExtended Trading$52.01 +1.32 (+2.61%) As of 10/2/2026 08:00 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more. Add Compare Share Share Stock Analysis Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFDA EventsFinancialsInsider TradesNews and TrendsOwnershipSEC FilingsShort Interest About Bright Minds Biosciences Stock (NASDAQ:DRUG) View Price History Chart DataSkip Price History Chart 1 Day 5 Days 30 Days 90 Days 1 Year Advanced 1 Day 1 Day 5 Days 30 Days 90 Days 1 Year Advanced Show volume Show extended hours Get DRUG alerts:Sign Up Key Stats Today's Range$48.75▼$51.0450-Day Range$49.21▼$84.7452-Week Range$48.53▼$123.75Volume154,688 shsAverage Volume92,454 shsMarket Capitalization$493.21 millionP/E RatioN/ADividend YieldN/APrice Target$143.83Consensus RatingModerate Buy Company Overview Bright Minds Biosciences Inc. is a biotechnology company focused on developing next-generation therapeutics for neuropsychiatric and neurological disorders. The company’s research is centered on selective serotonin receptor agonists designed to address conditions involving disrupted brain signaling while potentially avoiding some of the adverse effects associated with older serotonergic medicines. Bright Minds’ lead product candidate is BMB-101, a selective 5-HT2C receptor agonist being developed for disorders including epilepsy and other conditions involving neuronal hyperexcitability. The company has also pursued additional compounds targeting neuropsychiatric indications such as substance-use disorders, obesity and binge-eating disorder. Its development programs are intended to advance through clinical testing and, if successful, regulatory review. Bright Minds Biosciences is based in Vancouver, British Columbia, Canada, and conducts research and drug-development activities through its biotechnology operations. The company’s shares trade on the Nasdaq Capital Market under the symbol DRUG.AI Generated. May Contain Errors. Read More Bright Minds Biosciences Stock Analysis - MarketRank™See Top-Rated MarketRank™ Stocks52nd Percentile Overall ScoreDRUG MarketRank™: Bright Minds Biosciences scored higher than 52% of companies evaluated by MarketBeat, and ranked 462nd out of 887 stocks in the healthcare sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation. Analyst's Opinion4.5 / 5Analyst RatingModerate Buy Consensus RatingBright Minds Biosciences has received a consensus rating of Moderate Buy. The company's average rating score is 2.90, and is based on 1 strong buy rating, 7 buy ratings, 2 hold ratings, and no sell ratings.Upside PotentialBright Minds Biosciences has a consensus price target of $143.83, representing about 183.8% upside from its current price of $50.69.Amount of Analyst CoverageBright Minds Biosciences has been the subject of 6 research reports in the past 90 days, demonstrating strong analyst interest in this stock.Read more about Bright Minds Biosciences' stock forecast and price target. Earnings and Valuation0.0 / 5Proj. Earnings GrowthDecreasing Earnings GrowthEarnings for Bright Minds Biosciences are expected to decrease in the coming year, from ($2.93) to ($6.77) per share.Price to Earnings Ratio vs. the MarketThe P/E ratio of Bright Minds Biosciences is -24.37, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Earnings Ratio vs. SectorThe P/E ratio of Bright Minds Biosciences is -24.37, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Book Value per Share RatioBright Minds Biosciences has a P/B Ratio of 6.09. P/B Ratios above 3 indicate that a company could be overvalued with respect to its assets and liabilities.Read more about Bright Minds Biosciences' valuation and earnings. Short Interest0.0 / 5Short Interest LevelBearish Percentage of Shares Shorted16.70% of the float of Bright Minds Biosciences has been sold short.Short Interest Ratio / Days to CoverBright Minds Biosciences has a short interest ratio ("days to cover") of 12, which indicates bearish sentiment.Change versus previous monthShort interest in Bright Minds Biosciences has recently increased by 4.29%, indicating that investor sentiment is decreasing. Dividend0.0 / 5Dividend StrengthN/A Dividend YieldBright Minds Biosciences does not currently pay a dividend.Dividend GrowthBright Minds Biosciences does not have a long track record of dividend growth. News and Social Media3.6 / 5News Sentiment0.77 News SentimentBright Minds Biosciences has a news sentiment score of 0.77. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a higher news sentiment than the 0.44 average news sentiment score of Healthcare companies.News Coverage This WeekMarketBeat has tracked 5 news articles for Bright Minds Biosciences this week, compared to 3 articles on an average week.MarketBeat Follows1 people have added Bright Minds Biosciences to their MarketBeat watchlist in the last 30 days. Company Ownership1.2 / 5Insider TradingN/A Insider Buying vs. Insider SellingIn the past three months, Bright Minds Biosciences insiders have not sold or bought any company stock.Percentage Held by Insiders42.66% of the stock of Bright Minds Biosciences is held by insiders. A high percentage of insider ownership can be a sign of company health.Percentage Held by Institutions40.52% of the stock of Bright Minds Biosciences is held by institutions. High institutional ownership can be a signal of strong market trust in this company.Read more about Bright Minds Biosciences' insider trading history. Receive DRUG Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Bright Minds Biosciences and its competitors with MarketBeat's FREE daily newsletter. Submit View SMS TermsSMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy. DRUG Stock News HeadlinesBright Minds Biosciences (NASDAQ:DRUG) Stock Moved Down to Sell by Wall Street ZenOctober 3 at 1:13 AM | americanbankingnews.comBright Minds Biosciences to Participate in the 2026 FPWR Research Symposium and PWS Family ConferenceSeptember 30, 2026 | globenewswire.comA new type of AI could unleash gains of up to 10,000%A new AI category called Accelerated AI is starting to gain traction, and most investors haven't caught on yet. Early movers in past technology shifts have seen outsized results, and this emerging niche is drawing comparisons. Get the name and ticker of the leading Accelerated AI company making waves right now.October 4 at 1:00 AM | Brownstone Research (Ad)Bright Minds Biosciences (DRUG) Receives a Rating Update from a Top AnalystSeptember 24, 2026 | theglobeandmail.comPiper Sandler Sticks to Its Buy Rating for Bright Minds Biosciences (DRUG)September 19, 2026 | theglobeandmail.comBright Minds Biosciences to Present at Upcoming ConferencesSeptember 4, 2026 | globenewswire.comBright Minds: BMB-101 Takes Center Stage Ahead Of Phase 3 Pivotal TrialsAugust 10, 2026 | seekingalpha.comVistagen Appoints Douglas J. Williamson to its Board of DirectorsJuly 31, 2026 | globenewswire.comSee More Headlines DRUG Stock Analysis - Frequently Asked Questions How have DRUG shares performed this year? Bright Minds Biosciences' stock was trading at $78.04 at the beginning of the year. Since then, DRUG shares have decreased by 35.0% and is now trading at $50.69. How were Bright Minds Biosciences' earnings last quarter? Bright Minds Biosciences Inc. (NASDAQ:DRUG) posted its quarterly earnings results on Friday, August, 14th. The company reported ($0.17) EPS for the quarter, beating analysts' consensus estimates of ($1.22) by $1.05. When did Bright Minds Biosciences' stock split? Shares of Bright Minds Biosciences reverse split on Friday, July 14th 2023.The 1-5 reverse split was announced on Friday, July 14th 2023. The number of shares owned by shareholders was adjusted after the closing bell on Friday, July 14th 2023. An investor that had 100 shares of stock prior to the reverse split would have 20 shares after the split. How do I buy shares of Bright Minds Biosciences? Shares of DRUG stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. What other stocks do shareholders of Bright Minds Biosciences own? Based on aggregate information from My MarketBeat watchlists, some other companies that Bright Minds Biosciences investors own include HubSpot (HUBS), Blink Charging (BLNK), ConocoPhillips (COP), Netflix (NFLX), SoFi Technologies (SOFI). Company Calendar Last Earnings8/14/2026Today10/04/2026Next Earnings (Estimated)12/22/2026Fiscal Year End9/30/2027Get Stock Alerts Health Indicator TradeSmith's Health IndicatorA long-term volatility-based measure designed for securities held 12 months or longer.Green: Strong and healthy uptrend with normal pullbacks.Yellow: Significant pullback but still within expected volatility.Red: Dropped beyond expected volatility; considered unhealthy. Yellow Zone (1w+) 1-Year History Oct 25 Jan 26 Apr 26 Jul 26 Oct 26 For the last 10 days, DRUG's financial health has been in the Yellow zone, according to TradeSmith. Industry, Sector and Symbol Stock ExchangeNASDAQ SectorHealthcare Industry Pharmaceuticals Sub-IndustryPharmaceuticals Current SymbolNASDAQ:DRUG CIK1827401 Webbrightmindsbio.com Phone64-7407-2515FaxN/AEmployees25Year Founded2019Price Target and Rating Average Price Target for Bright Minds Biosciences$143.83 High Price Target$220.00 Low Price Target$80.00 Potential Upside/Downside+183.8%Consensus RatingModerate Buy Rating Score (0-4)2.90 Research Coverage10 Analysts Profitability EPS (Trailing Twelve Months)($2.08) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income-$8.74 million Net MarginsN/A Pretax MarginN/A Return on Equity-12.46% Return on Assets-12.30% Debt Debt-to-Equity RatioN/A Current Ratio122.00 Quick Ratio122.00 Sales & Book Value Annual SalesN/A Price / SalesN/A Cash FlowN/A Price / Cash FlowN/A Book Value$8.33 per share Price / Book6.09Miscellaneous Outstanding Shares9,730,000Free Float5,580,000Market Cap$493.21 million OptionableNot Optionable Beta-5.22 Social Links 10 Best Stocks to Own in Fall 2026AI spending is reshaping the market, and the opportunity extends far beyond the biggest chipmakers. Discover 10 stocks set to benefit from powerful trends in AI infrastructure, cloud computing, energy, capital returns, and consumer growth this fall.Get This Free Report This page (NASDAQ:DRUG) was last updated on 10/4/2026 by MarketBeat.com Staff. From Our PartnersElon Warns "America Will Go Bankrupt". Trump's Plan Inside.National debt just crossed 40 trillion dollars, and Elon Musk says America is 1,000% going to go bankrupt with...American Hartford Gold | SponsoredWATCH THIS BEFORE DECEMBER 8th!!James Altucher says a quiet government filing could reveal Elon Musk's biggest move yet, and almost nobody has...Paradigm Press | SponsoredYour book attachedBill Poulos is giving away his 'Safe Trade Options Formula' book for free - but only for a limited time throug...Profits Run | SponsoredSmall Colorado Company (Backed by Sam Altman) Could Save U.S. Power GridA small Colorado company has secured rights to technology that could prevent the U.S. public power grid from c...Altimetry | SponsoredI'm giving you a space stock today. Free.On December 8th, $600 billion in frozen SpaceX stock comes loose. Dylan Jovine says one simple purchase in any...Behind the Markets | SponsoredHow Elon’s Empire Ends (and how to profit)Marc Chaikin, the 60 year Wall Street veteran whose Chaikin Money Flow indicator sits on every Bloomberg termi...Chaikin Analytics | SponsoredMy top 3 AI picks for the next decadeAlexander Green bought Apple in 1996, recommended Nvidia at a split-adjusted 66 cents in 2004, and picked up A...The Oxford Club | SponsoredALERT: Drop these 5 stocks before the market opens tomorrow!The Wall Street Journal is already raising the alarm about a potential market crash, and Weiss Ratings researc...Weiss Ratings | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Bright Minds Biosciences Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Bright Minds Biosciences With A Colleague Link copied to clipboard. Unlock superior investment research and tools. Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools and reports. Get MarketBeat All Access MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In Email Me a Login Link or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Free DRUG Stock Alerts